We are live on ! Find out more
FLNA

Filana Therapeutics

87 hedge funds and large institutions have $154M invested in Filana Therapeutics in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,000% more call options, than puts

Call options by funds: $612K | Put options by funds: $12K

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

43% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 21

16% more funds holding

Funds holding: 7587 (+12)

13% more capital invested

Capital invested by funds: $137M → $154M (+$17.2M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
87
Holders Change
+12
Holders Change %
+16%
% of All Funds
2.5%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
24
Increased
30
Reduced
21
Closed
12
Calls
$612K
Puts
$12K
Net Calls
+$600K
Net Calls Change
-$341K
Name Holding Trade Value Shares
Change
Change in
Stake
SO
51
STRS Ohio
Ohio
$275K +$253K +6,843 New
SG Americas Securities
52
SG Americas Securities
New York
$241K +$221K +5,980 New
VKH
53
Virtu KCG Holdings
New York
$206K +$190K +5,121 New
VOYA Investment Management
54
VOYA Investment Management
Georgia
$188K +$172K +4,660 New
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$183K +$168K +4,543 New
MLICM
56
Metropolitan Life Insurance Company (MetLife)
New York
$181K +$166K +4,489 New
CIA
57
Capital Impact Advisors
Massachusetts
$179K +$165K +4,458 New
PP
58
PDT Partners
New York
$176K +$78.7K +2,128 +95%
ARTA
59
A.R.T. Advisors
New York
$169K -$10.9K -295 -7%
JP Morgan Chase
60
JP Morgan Chase
New York
$163K -$80.3K -2,170 -35%
NFA
61
Nationwide Fund Advisors
Ohio
$161K +$148K +4,006 New
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$155K +$133K +3,592 +1,371%
Two Sigma Advisers
63
Two Sigma Advisers
New York
$149K +$58.7K +1,586 +75%
CCMU
64
Cheyne Capital Management (UK)
United Kingdom
$144K -$421K -11,370 -76%
AIG
65
American International Group
New York
$143K +$132K +3,555 New
BA
66
BlackRock Advisors
Delaware
$141K +$82.8K +2,238 +176%
AG
67
Algert Global
California
$112K +$103K +2,778 New
BIM
68
Bogle Investment Management
Massachusetts
$107K -$808K -21,848 -89%
ProShare Advisors
69
ProShare Advisors
Maryland
$107K +$98K +2,648 New
Principal Financial Group
70
Principal Financial Group
Iowa
$72K +$65.9K +1,780 New
CSS
71
Cubist Systematic Strategies
Connecticut
$59K +$53.8K +1,454 New
RFC
72
Russell Frank Company
Washington
$57K +$73.5K +1,987 New
CCMH
73
Cornerstone Capital Management Holdings
New York
$50K +$46K +1,243 New
U
74
UBS
Switzerland
$29K -$569K -15,372 -96%
Citadel Advisors
75
Citadel Advisors
Florida
$27K -$436K -11,794 -95%

FLNA Hedge Fund Activity: Q2 2014 in Review

87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2014, worth a combined $154M — up 13% from $137M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new FLNA positions and 12 closed out — a net gain of 12 holders — while 30 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $4.44M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.29M sold.

  • 87 institutional investors held Filana Therapeutics (FLNA) as of Q2 2014, up from 75 in Q1 2014.
  • Funds reported $154M of Filana Therapeutics stock for Q2 2014, up 13% quarter-over-quarter.
  • 24 funds opened new Filana Therapeutics positions in Q2 2014 and 12 closed out, a net change of +12 holders.
  • The largest Filana Therapeutics buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $4.44M added.
  • The largest Filana Therapeutics seller in Q2 2014 was Broadfin Capital, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2014.